Rare Diseases
Delivering solutions for the most complex clinical challenges.
Expertise that delivers results
Rare disease clinical research requires scientific depth, operational precision, and a patient-centric approach — capabilities Aixial Group has built over 20 years supporting sponsors globally.
Why rare disease require specialist expertise
Rare diseases occur individually in small populations but affect millions worldwide making traditional clinical development approaches inefficient or infeasible. These trials face limited patient numbers, complex natural history and variable endpoints requiring bespoke design, recruitment, and execution strategies. Expertise in these areas is critical to trial success.
Aixial team, your trusted partner
Our global, multidisciplinary team brings the scientific, medical, operational, and regulatory expertise needed to navigate the challenges of rare disease clinical trials, to deliver successful outcomes to accelerate the development of life-changing therapies.
- Medical & scientific leadership: Integrated MD and PhD‑level expertise in rare disease biology, clinical trial design, endpoint selection, and benefit–risk assessment
- Patient recruitment & retention: Proven strategies for enrolling and retaining small, geographically dispersed patient populations
- Global site network: Access to specialised rare disease centres across APAC, Europe, and the Americas
- Operational excellence: Tailored logistics, supply management, site activation, and decentralised execution for complex protocols
- Regulatory expertise: Orphan drug pathways, paediatric and accelerated approvals, and multi‑region compliance oversight
- Risk management: Anticipating and mitigating operational, regulatory, and logistical challenges
- Cross-phase experience: First-in-Human to Phase III programmes across diverse indications
Ask us about
- Regulatory pathway selection
- Patient enrolment and logistics
- Trial design
- Country and site selection
- Medicinal product logistics
- Data collection and delivery
Rare Disease trials we’ve supported
With a portfolio of hundreds of rare‑disease studies, Aixial has developed unmatched insight across varied indications, complex patient pathways, and global operational environments. Our teams support programs from first‑in‑human through later‑phase development, helping sponsors navigate the unique challenges of rare‑disease research.
- Phase I – IV, including FIH and RWE
- Adult and paediatric populations
- APAC, Europe, North America
Extensive Rare Disease expertise across indications and clinical stages
Acromegaly
Alpha-1 Antitrypsin Deficiency (AATD)
Alpha – Mannosidosis
APDS
Autoimmune indications
Beta-thalassemia
Cluster Headache
Cushing’s Disease
Cystic Fibrosis
Eisenmenger Sydrome
Fabry Disease
Fragile X
Hereditary Angioedema
Hurler’s Disease
Inclusion Body Miositis
Inherited Metabolic Disorders
Lipoprotein Lipase Deficiency
Malignant rare diseases
Multiple Sclerosis
Myasthenia Gravis
Myositis
Netherton Syndrome
Nevoid Basal Cell Carcinoma Syndrome
NOMID/CINCA Syndrome
Noonan Syndrome
Paroxysmal Nocturnal Hemaglobinuria
PASLI Disease
Pediatric Hypertension
Pemphigus Vulgaris
Phosphomannomuttase
Pigmented Villonodular Synovitis
Primary Biliary Cholangitis
Primary Biliary Cirrhosis
Primary Hyperaldosteronism
Pulmonary Fibrosis
Raynaud’s Disease
Rheumatoid Arthritis
Sarcoidosis
Sickle Cell Disease
Sjogren’s Syndrome
Sjogren’s Syndrome
Spinal Muscular Atrophy (SMA)
Systemic Sclerosis
Tuberculosis
Type 1 Spinal Muscular Atrophy
Uveitis
Visceral Leishmaniasis
Wilson’s Disease
X-Linked Severe Combined Immunodeficency
Together, these insights reinforce Aixial’s leadership in rare‑disease research and our ability to deliver smart, scalable solutions that help sponsors move breakthrough therapies forward with confidence.
How can we support your next project?
Whether you’re looking for a protocol review or a proposal,
simply reach out to us by filling our request for proposal.
